# Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

> **NCT04345601** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 28 (actual)

## Conditions studied

- Sars-CoV2
- Acute Respiratory Distress Syndrome
- COVID-19

## Interventions

- **BIOLOGICAL:** Mesenchymal Stromal Cells
- **OTHER:** Supportive Care

## Key facts

- **NCT ID:** NCT04345601
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-12
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345601, "Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04345601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*